Transaction DateRecipientSharesTypePriceValue
10th December 2020Stacey M Stevens20,000Open or private sale$13.00$260,000.00
8th December 2020R. Scott Areglado15,000Exercise of derivative$6.00$90,000.00
8th December 2020R. Scott Areglado15,000Open or private sale$12.00$180,000.00
4th December 2020Stacey M Stevens18,665Open or private sale$11.28$210,481.47
4th December 2020Stacey M Stevens18,665Exercise of derivative$6.68$124,682.20
3rd December 2020Stacey M Stevens1,100Open or private sale$11.07$12,180.96
3rd December 2020Stacey M Stevens1,100Exercise of derivative$6.68$7,348.00
8th October 2020Stacey M Stevens15,873Exercise of derivative$2.27$36,031.71
8th October 2020Stacey M Stevens15,873Open or private sale$10.00$158,730.00
9th September 2020Andy Sassine10,000Open or private sale$9.47$94,746.00
I Cad
I Cad logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


iCAD, Inc. engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. It operates through the Cancer Detection and Cancer Therapy business segments. The company was founded in 1984 and is headquartered in Nashua, NH.


Ticker: ICAD
Sector: Technology Services
Industry: Packaged Software
SEC Central Index Key (CIK): 749660
Employees: 138
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $24 M (0%)
Inventory, Net: $3 M (0%)
Assets, Current: $36 M (22%)
Property, Plant and Equipment, Net: $590 Th (7%)
Assets: $48 M (14%)
Accounts Payable, Current: $1 M (-28%)
Accrued Liabilities, Current: $5 M (-22%)
Liabilities, Current: $13 M (-32%)
Liabilities: $21 M (-41%)
Common Stock, Value, Issued: $231 Th (18%)
Common Stock, Shares, Issued: $23 M (17%)
Additional Paid in Capital, Common Stock: $266 M (15%)
Retained Earnings (Accumulated Deficit): $239 M (6%)
Treasury Stock, Value: $14 Th (0%)
Treasury Stock, Shares: $2 M (0%)
Stockholders' Equity (Parent): $26 M (0%)
Liabilities and Equity: $48 M (14%)
Revenue: $6 M (0%)
Cost of Revenue: $1 M (-62%)
Gross Margin: $4 M (0%)
Research and Development: $2 M (-54%)
Sales and Marketing: $3 M (-57%)
General and Administrative Expenses: $2 M (-54%)
Operating Income/Loss: $2 M (-62%)
Other Income, net: $82 Th (-98%)
Provision for income taxes: $5 Th (0%)
EPS (basic): $0.11 (-83%)
EPS (diluted): $0.11 (-83%)